Overview
Injective vs MANA is one of the most watched crypto matchups. Beyond headline prices, this comparison blends market structure, technical readings and probabilistic context without promising outcomes.
Quick winners
Full comparison
| Metric | INJ | MANA |
|---|---|---|
| Price | $5.13 | $0.066700 |
| Market Cap | $490.41M | $130.47M |
| FDV | — | — |
| Volume 24h | $2.59M | $245,156.84 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 213.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | MANA |
|---|---|---|
| 1H | — | — |
| 24H | +3.91% | +1.06% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | MANA |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 59.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Indicator stacks for INJ/MANA currently lean on separate regimes: neutral versus bearish. Treat MACD and RSI as context, not as standalone entry triggers.
Fundamentals
| Metric | INJ | MANA |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
MANA
Pros and cons
Pros of Injective
- Higher ranking for Injective can translate into tighter spreads on major venues.
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
Cons of Injective
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
Pros of MANA
- Active volume bursts on MANA sometimes precede sharper tactical moves.
- Diversifying versus Injective with MANA can change portfolio factor exposure.
- If technical momentum aligns, MANA may outperform on medium-term windows.
- Narrative optionality around MANA can reprice quickly when catalysts appear.
Cons of MANA
- Trend failures on MANA often travel faster than on more established assets.
- Weaker market-cap standing may leave MANA more exposed to liquidity droughts.
- Higher volatility on MANA cuts both ways and demands stricter risk limits.
- Smaller book depth versus large caps can increase slippage for MANA.
Which looks stronger right now?
Data currently points to a probabilistic edge for Injective on size and Injective on activity. Neither reading guarantees future returns.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #99; MANA shows $130.47M and #213. Where liquidity and flow matter, watch Injective. Where durability matters, watch Injective. AI composite scores (48.70/58.20) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or MANA?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or MANA?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and MANA.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.